Anforderung an die Patientenführung onkologischer Patienten und ...
Anforderung an die Patientenführung onkologischer Patienten und ...
Anforderung an die Patientenführung onkologischer Patienten und ...
Erfolgreiche ePaper selbst erstellen
Machen Sie aus Ihren PDF Publikationen ein blätterbares Flipbook mit unserer einzigartigen Google optimierten e-Paper Software.
ASCO-Guidelines: keine Tumormarker-Verlaufskontrollen in der Nachsorge<br />
CA 15-3 <strong>und</strong> CEA als Tumormarker für Mamma-Ca<br />
Screening<br />
Diagnosis/<br />
Staging<br />
Monitoring<br />
Response to<br />
Therapy<br />
Surveill<strong>an</strong>ce<br />
CA 15-3 <strong>an</strong>d CEA are not recommended to use as screening tests for breast<br />
c<strong>an</strong>cer.<br />
CA 15-3 <strong>an</strong>d CEA are not recommended for diagnosing or staging breast c<strong>an</strong>cer.<br />
• CA 15-3 <strong>an</strong>d CEA in conjunction with diagnostic imaging, history <strong>an</strong>d<br />
physical exam<br />
• insufficient data for the use of CA 15-3 <strong>an</strong>d CEA alone for monitoring<br />
response to treatment<br />
• When no readily measurable disease, increasing levels of CA 15-3 <strong>an</strong>d CEA may<br />
be used to indicate treatment failure.<br />
• Use caution while monitoring during the first 4-6 weeks of a new therapy to<br />
avoid spurious early rises.<br />
CA 15-3 <strong>an</strong>d CEA are not recommended for monitoring patients for<br />
recurrence after primary breast c<strong>an</strong>cer therapy.<br />
nach: ASCO 2007, Update of Recommendations for the Use of Tumor Markers in Breast C<strong>an</strong>cer<br />
Harris et al., J Clin Oncol. 2007;25:33:5287-5312.
Change language